Needham analyst Ami Fadia has maintained their neutral stance on MRUS stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia’s rating is based on a combination of factors, including the recent data presented by Merus, which although impressive, is derived from a small and immature dataset. The efficacy results for Peto in both first-line and second-line colorectal cancer (CRC) show promising response rates when compared to competitors, but the limited size of the dataset raises questions about the long-term durability of these results.
Additionally, while the data suggests potential competitiveness in other indications, such as head and neck squamous cell carcinoma (HNSCC), the comparisons are not directly applicable due to differences in datasets. Given these considerations, Fadia maintains a cautious stance, opting for a Hold rating as the data does not yet provide a strong enough basis for a more definitive recommendation.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $96.00 price target.